3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
4
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplastic Syndromes, Hereditary
1
Melanoma
1
Kidney Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Colonic Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Interventions
pembrolizumab
49
Nivolumab
22
Cyclophosphamide
20
fludarabine
13
Paclitaxel
9
Ipilimumab
9
atezolizumab
8
aldesleukin
8
Specimen Handling
8
Interleukin-2
7
Carboplatin
7
Magnetic Resonance Spectroscopy
6
Docetaxel
6
Biopsy
6
cemiplimab
5
fludarabine phosphate
4
durvalumab
4
Taxes
4
Gemcitabine
4
Drug Therapy
4
spartalizumab
3
poly ICLC
3
epacadostat
3
X-Rays
3
Leucovorin
3
Injections
3
Immunoglobulin G
3
Filgrastim
3
Cisplatin
3
CTLA-4 Antigen
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Genetic Counseling
×
Gynecologic
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled